Can Long-term Antifungal Therapy Be an Alternative to Surgery in Pulmonary Aspergilloma?*

Pulmoner Aspergillomada Uzun Dönem Antifungal Tedavi Cerrahiye Alternatif Olabilir mi?

Abstract
Pulmonary aspergilloma is one of the clinical conditions with high mortality and morbidity in immunosuppressed patients. Surgical resection has been the leading treatment option; however, surgical treatment involves some risk of local and systemic dissemination and there are also patients who are functionally inappropriate to be treated surgically. In this paper, we present two patients with bilateral PA who underwent surgical and antifungal treatment. Antifungal therapy with voriconazole that was successful for both of our patients might be a promising approach to a group of PA patients who are not appropriate for surgery.

Keywords: pulmonary aspergilloma; voriconazole; surgery; fungus ball

Öz
Pulmoner aspergilloma (PA), immünsüprese hastalarda yüksek mortalite ve morbiditi klinik durumlandırır. Tedavide sıklıkla cerrahi rezeksiyon tercih edilir; fakat cerrahide lokal ve sistemik yayılım riski mevcuttur ve ayrıca cerrahi tedavi fonksiyonel olarak uygun olmayan hastalar da vardır. Bu çalışmada cerrahi ve antifungal tedavi uygulanmış olan bilateral PA’lı iki hastayı sunmaktayız. Vorikonazol ile yapılan ve iki hastamızda başarılı olan antifungal tedavi, cerrahiye uygun olmayan bir grup PA hastası için şanfordan bir yaklaşım olabilir.

Anahtar Sözcüklər: pulmoner aspergilloma; vorikonazol; cerrahi; mantar topu

* This paper was presented as a poster at the National Lung Health Meeting held on 14–18 March 2018 in Antalya.
INTRODUCTION

Pulmonary aspergilloma (PA) is the saprophytic colonization of *Aspergillus fumigatus* in the existing cavities of the lung parenchyma (1,2). Especially in immunosuppressed patients (with a history of bone marrow transplantation, malignant hematological disorders, high-dose use of corticosteroids, or chemotherapeutic regimens), pulmonary aspergillosis may cause clinical outcomes with high morbidity and mortality (1–4). Aspirated aspergillus spores proliferate and turn into invasive hyphae in patients with impaired phagocytic functions that progress to broncho- and/or angio-invasive aspergillosis in deep immunosuppression or to mycetoma/fungus ball in mild to moderate immunosuppression. Invasive aspergillosis and mycetoma usually have different clinical courses (1–4).

Hemoptysis is the major life-threatening acute clinical condition caused by PA. There is also some risk of developing invasive aspergillosis or fungal septicemia, which have even higher morbidity and mortality (5,6). Treatment and follow-up of patients with PA still lack a well-defined evidence-based algorithm. Surgery has been the leading treatment option in current practice (1,7); however, it also involves some risk of local or systemic dissemination, resulting in invasive aspergillosis or fungemia (2,6). Adjuvant use of mold-active antifungal drugs has been shown to be effective for preventing dissemination (8,9), despite the contrary feedbacks regarding its use involving systemic side effects with unexpectedly low prevention benefits (1).

In this paper we present two cases of bilateral PA. Bilateral surgical excision had been planned for both patients, who received adjuvant antifungal treatment after the operation for their lesions on one side. The patients’ lesions on the non-operated side regressed during the follow-up period, eliminating the need for further surgery.

Case 1

A 56-year-old female patient had had diagnosed sarcoidosis for the last 3 years. She was an active smoker and had been smoking 20 packs of cigarettes per year. For the last 7 months, corticosteroids were added to her treatment. She had a sudden attack of hemoptysis with dyspnea and productive cough. In the chest X-Ray, a cavitary lesion located on the left lung and suspicious infiltration in the right lung were seen (Figure 1a). Computerized tomography (CT) of the thorax revealed a 4x3-cm cavitary lesion with a thick wall. A lobulated soft tissue density as a mycetoma–fungus ball was also detected inside this cavitary lesion. In the right lung there were infiltrative areas (Figure 1b). The fiber-optic bronchoscopic examination revealed bleeding from the left upper lobe without any additional pathology in the airway. In the Giemsa stain of bronchoalveolar lavage (BAL), there were polymorphonuclear leukocytes and bronchial epithelial cells. BAL and sputum culture yielded normal oral flora with no signs of fungal elements in the Gram and Giemsa staining. As the hemoptysis of the patient progressed, we performed a left upper lobectomy by a left anterior thoracotomy to avoid any life-threatening condition. The postoperative period was uneventful and the patient was discharged on the 6th postoperative day. The histopathological examination revealed mycetoma in the bronchiectasis areas in the lung parenchyma. The patient did very well during the postoperative period and had no hemoptysis. In the 15th month there was a new episode of hemoptysis and dyspnea. Radiological evaluation showed a recurrence of a cavitary lesion in the existing left lower lobe. There was also a bronchopleural fistula (BPF) and newly developed cavitary lesions in the bacillary segments of the right lower lobe. Antifungal treatment with IV voriconazole (loading dose 6 mg/kg, maintenance dose 4 mg/kg q12h) was initiated and surgery was planned for the patient. We performed anterolateral thoracotomy and the cavitary lesion inside the thoracic cavity was resected. The BPF was also repaired via thoracomyoplasty by excising 3 ribs, with a muscle flap placed in the thoracic cavity. The postoperative period was uneventful and the patient was discharged on the 7th postoperative day (Figure 1c). The physical and mental condition of the patient was not appropriate for the contralateral surgery. Accordingly, it was decided to continue antifungal treatment with voriconazole (2x200mg per oral). No voriconazole-related side effect was observed during the following 6 months of treatment. The follow-up computed tomography (CT) scan of the thorax showed a total regression of the cavitary lesion in the right lung, which turned into a soft tissue remnant (Figure 1d).
Case 2
A 53-year-old female patient with acute myeloid leukemia (AML) for 4 years was re-hospitalized for chemotherapy due to disease recurrence on the 4th day of the treatment, and she had febrile neutropenia. Blood, urine and sputum cultures did not confirm any bacterial growth. Her chest X-ray revealed clear diffuse infiltration in the left lung, compatible with opportunistic fungal pneumonia, particularly invasive pulmonary aspergillosis (Figure 2a). The serum galactomannan test (Aspergillus antigen) was positive. She was under fluconazole prophylaxis since the onset of her chemotherapy. The regimen was shifted to a mold-active antifungal with liposomal amphotericin-B 3 mg/kg/d IV upon infectious diseases consultation. Despite this treatment her fever continued and she had hemoptysis on the 6th day. CT of the chest showed a centrally located cavitary lesion in the left lung lingula section. The lesion had a diameter of 3.5 cm and was surrounded with ground-glass opacities. In the right lung there were similar nodular and cavitary lesions suspected to be aspergilloma (Figure 2b).

Figure 1a. Chest X-ray showing a cavitary lesion on the left upper zone (black arrow) and a suspicious infiltrative lesion on the right middle zone (white arrow).

Figure 1b. CT of the chest revealed a 4x3-cm cavitary lesion with a thick wall in the left lung. Inside the lesion there was a 1x1-cm lobulated soft tissue surrounded with infiltration (black arrow). There was an infiltrative pre-cavitary area in the right middle lobe (white arrow).

Figure 1c. Chest X-ray after bronchopleural fistula repair surgery. Thoracomyoplasty by excising 3 ribs was performed and a muscle flap was placed in the left hemithorax.

Figure 1d. CT of the chest revealed that the previously defined lesion in the right lung regressed and turned into a soft tissue density area (black arrow), with secondary changes due to the previous interventions in the left hemithorax.

L-AmphB
was switched to voriconazole (200mg q12h IV), which is superior to other antifungals against aspergillus species. As the hemoptysis continued, she had FOB, with an active bleeding from the left lingular bronchus. As the symptoms persisted and the patient needed chemotherapy for her AML, a surgical resection was planned. We performed a uniportal video-assisted thoracoscopic surgery (VATS) left lingulectomy. The postoperative course was uneventful and the patient’s chest tube was pulled off before her discharge on the 2nd postoperative day. The patient continued her antifungal treatment with voriconazole (2x200mg per oral). The initial plan was surgical excision for the right side and accordingly the patient had a CT thorax scan in the 5th week. The CT scans showed that the pre-existing lesions on the right almost totally regressed. This made a change in our surgical plan for the right side, and we decided to follow up the patient under antifungal treatment. In the 4th month she was quite fine clinically and the disease appeared radiologically to have regressed (Figure 2d).

RESULTS
The cavitary lesions on the non-operated sides regressed nearly totally in both patients. No prominent side effect related to the antifungal treatment was observed. Patient 1 is in the 41st and Patient 2 5th month of follow-up, with no clinical problem due to PA. Their primary diseases (sarcoidosis and AML) are also clinically under control.

DISCUSSION AND CONCLUSION
Aspergillus fumigatus is one of the most common fungal pathogens for invasive pulmonary infections in immunosuppressed patients (1–3,10). Because there is...
an ongoing construction process in our hospital and fungal spores are easily spread via air flow, the risk of exposure is extremely high for all patients regardless of inpatient or outpatient setting. The most common clinical form of aspergillus infection in respiratory system is invasive pulmonary aspergillosis (IPA) in immunosuppressed patients, particularly those with hematological cancer. Pulmonary aspergilloma is also common in patients with mild to moderate immunosuppression. (10). PA may develop inside the cavities secondary to localized emphysema, sarcoidosis, bronchiectasis, tuberculosis-related bullae, cystic lesions, or cavities formed by necrotizing infections. Among those, pulmonary tuberculosis is the leading cause for cavity formation with a rate of 11% (11). Aspergillus spores may remain silent within the alveoli for years and reactivate in case of neutropenia due to cytotoxic treatment. The most common symptoms are fever, productive cough and hemoptysis, which is a sign of vessel invasion (1,3) With a mortality of up to 50%, hemoptysis is the most serious clinical condition requiring urgent attention (4,13–15). Surgery is preferred in cases of aspergilloma (so-called “fungus ball”) where medical treatment is less effective. However the surgical procedure itself has a mortality of 1 to 22% and morbidity 23 to 78% (16–19). Use of mold-active adjuvant (prior to and after surgery) antifungal treatment has not been proven to be superior to surgery alone (1). Also some groups of patients may not be good candidates for surgery due to their existing risks or poor functional lung capacity. Accordingly, alternative evidence-based treatment options are needed.

In conclusion, both of our patients had bilateral PA and underwent unilateral surgery. The first patient was not appropriate for the contralateral surgery due to impaired lung function and the second was in the waiting period. Both showed a dramatic regression in their cavitary lesions with adequate antifungal treatment. Long-term outpatient use of voriconazole that was successful for both of our patients might be a promising approach to a group of PA patients who are not appropriate for surgery, although our results need to be supported by further research.

REFERENCES
1. Sagan D, Goździuk K. Surgery for pulmonary aspergilloma in immunocompetent patients: no benefit from adjuvant antifungal pharmacotherapy. Ann Thorac Surg. 2010;89(5):1603–10.
2. Lee JG, Lee CY, Park IK, et al. Pulmonary aspergilloma: analysis of prognosis in relation to symptoms and treatment. J Thorac Cardiovasc Surg. 2009;138:820–5.
3. Brik A, Salem AM, Kamal AR, et al. Surgical outcome of pulmonary aspergilloma. Eur J Cardiothorac Surg. 2008;34:882–5.
4. Park CK, Jheon S. Results of surgical treatment for pulmonary aspergilloma. Eur J Cardiothorac Surg. 2002;21:918–23.
5. Campbell JH, Winter JH, Richardson MD, Shankland GS, Banham SW. Treatment of pulmonary aspergilloma with itraconazole. Thorax. 1991;46:839–41.
6. Seki M, Maesaki S, Hashiguchi K, et al. Aspergillus fumigatus isolated from blood samples of a patient with pulmonary aspergilloma after embolization. Intern Med. 2000;39:188–90.
7. Jewkes J, Kay PH, Paneth M, Citron KM. Pulmonary aspergilloma: analysis of prognosis in relation to haemopt-
ysis and survey of treatment. Thorax. 1983;38:572–8.

8. Ho KM, Lipman J, Dobb GJ, Webb SA. The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis. Crit Care. 2005;9:R710–7.

9. Calandra T, Marchetti O. Clinical trials of antifungal prophylaxis among patients undergoing surgery. Clin Infect Dis. 2004;39(suppl 4):S185–92.

10. Scott SM, Takara T, Varkey B, et al. Thoracic mycotic and actinomycotic infections. In: W. Shields (ed.), General Thoracic Surgery. Baltimore: Williams and Wilkins; 1994:986.

11. British Thoracic and Tuberculosis Association. Aspergilloma and residual tuberculous cavities: the results of re-survey. Tubercle. 1970;51:227–45.

12. Odev K. Toraks Radyolojisi, 2. ed. Nobel Tip Kitabevleri; 2010:214–5.

13. Jewkes J, Kay PH, Paneth M, Citron KM. Pulmonary aspergilloma: analysis of prognosis in relation to haemoptysis and survey of treatment. Thorax. 1983;38:572–8.

14. el Oakley R, Petrou M, Goldstraw P. Indications and outcome of surgery for pulmonary aspergilloma. Thorax. 1997;52:813–5.

15. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408–15.

16. Babatasi G, Massetti M, Chapelier A, et al. Surgical treatment of pulmonary aspergilloma: current outcome. J Thorac Cardiovasc Surg. 2000;90:906–12.

17. Regnard JF, Icard P, Nicolasi M, et al. Aspergilloma: a series of 89 surgical cases. Ann Thorac Surg. 2000;69:898–903.